GVS advice ivermectin (Stromectol®)
The National Health Care Institute has completed its assessment whether the product ivermectin (Stromectol®) can be included in the Medicine Reimbursement System (GVS). Ivermectin is indicated for the treatment of scabies. The National Health Care Institute advises the Minister to include ivermectin (Stromectol®) in the GVS with reimbursement conditions as described on this page.
Indication for which reimbursement is requested
Ivermectin (Stromectol®) is indicated for the treatment of scabies, caused by Sarcoptes scabiei. The treatment of scabies is only indicated if the diagnosis has been established clinically and/or by parasitological examination.
National Health Care Institute's advice
The National Health Care Institute advises the Minister to include ivermectin (Stromectol®) in List 1B and List 2 of the GVS with the following reimbursement condition:
- only for administration to an insured person for scabies.